12/01/2021
protein Tdp43

A new mechanism for regulating the stability of amyotrophic lateral sclerosis associated protein Tdp43

Amyotrophic lateral sclerosis (ALS) is a progressive paralytic disease characterized by degenerative changes of motor neurons in the brain motor cortex, brain stem and spinal cord.
The core pathological change of ALS is the apoptosis of motor neurons in motor cortex and spinal cord, accompanied by the neuroinflammatory reaction of astrocyte, microglia and oligodendrocyte proliferation.
08/05/2021

Recombinant Human Somatropin(r-hGH)

The product is a protein composed of 191 amino acid residues or 192 amino acid residues with a methionine at the N-terminal, and appropriate excipients or stabilizers can be added. The amount of recombinant human growth hormone should be 90.0%~110.0% of the labeled amount.
07/05/2021

Classic question and answer in human growth hormone therapy

At present, the clinical application of human growth hormone is more and more extensive, and parents are paying more and more attention to the height of their children. Height is regarded as the first threshold for finding a job after entering the society. However, many parents still don't know much about human growth hormone, so many questions will inevitably arise during the medication period. Today, the editor will sort out your various doubts and answer them one by one.
30/04/2021

8 clinical applications of recombinant human growth hormone(HGH)

With the improvement of living standards, the average height of children has also increased significantly, but many parents still feel that their children cannot reach their "expected height".
In fact, most of them are normal, but there are still some short statures caused by lack of human growth hormone. At this time, attention should be paid to avoid missing the best expectations. Let us understand the drug that can make children grow taller-growth hormone.
15/04/2021
new crown virus vaccine

Recombinant Human Somatropin(r-hGH)

Other name:recombinant human growth hormone(r-hGH) The product is a protein composed of 191 amino acid residues or 192 amino acid residues with a methionine at the N-terminal, and appropriate excipients or stabilizers can be added. The amount of recombinant human growth hormone should be 90.0%~110.0% of the labeled amount.
14/04/2021
CD19/CD22 dual target car-t therapy

Classic question and answer in human growth hormone therapy

At present, the clinical application of human growth hormone is more and more extensive, and parents are paying more and more attention to the height of their children. Height is regarded as the first threshold for finding a job after entering the society. However, many parents still don't know much about human growth hormone, so many questions will inevitably arise during the medication period. Today, the editor will sort out your various doubts and answer them one by one.
10/04/2021

8 clinical applications of recombinant human growth hormone(HGH)

With the improvement of living standards, the average height of children has also increased significantly, but many parents still feel that their children cannot reach their “expected height”. In fact, most of them are normal, but there are still some short statures caused by lack of human growth hormone. At this time, attention should be paid to avoid missing the best expectations. Let us understand the drug that can make children grow taller-growth hormone. What is human growth hormone? Human growth hormone is divided into endogenous and exogenous. Endogenous growth hormone is secreted by growth hormone secreting cells in the anterior pituitary gland, and exogenous growth hormone is recombinant human growth hormone synthesized in vitro by genetic engineering technology. The synthetic recombinant human growth hormone has the same effect as the human endogenous growth hormone. The same role as hormones. Pharmacological effects of human growth hormone: Stimulate the differentiation and proliferation of epiphyseal chondrocytes, stimulate the growth of cartilage stromal cells, stimulate the differentiation and proliferation of osteoblasts, and cause acceleration of linear growth and widening of bones. Clinical application of human growth hormone Recombinant human growth hormone was first approved by the US FDA for growth hormone deficiency in 1985, and it has been approved for use in chronic renal insufficiency before kidney transplantation, idiopathic short stature, small for gestational age, and Turner synthesis Syndrome, noonan syndrome, Prader-Willi syndrome, etc. Since the advent of recombinant human growth hormone, it has brought hope for the treatment of children with short stature. The following introduces 8 clinical applications of recombinant human growth hormone. 1. Growth hormone deficiency Growth hormone deficiency is due to insufficient growth hormone secreted by the pituitary gland, resulting in short stature in children. However, growth hormone deficiency lacks the gold standard for diagnosis, and human growth hormone drug provocation test is currently an important basis for clinical diagnosis of growth hormone deficiency. However, this test still has certain limitations because it has a certain false positive rate and is difficult to be used as growth hormone. The gold standard for the diagnosis of deficiency should be comprehensively diagnosed. The basis for auxiliary diagnosis also includes ①The height is lagging behind the 3rd percentile of the height of normal healthy children of the same age and sex or less than 2 standard deviations; ②The height of children under 3 years of age is less than 7cm/year, from 3 years old to prepubertal <5cm/year, puberty (12~13 years old for boys, 10-11 years old for girls) <6cm/year; ③Symmetrically short, naive face; ④Bone age lags behind the actual age; ⑤The serum insulin-like growth factor 1 level is lower than normal Wait. Growth hormone deficiencies should be treated with growth hormone replacement therapy as soon as possible, starting from the age of 3, and adhere to the long-term, continuous, and individualized treatment principle. 2. Idiopathic short stature Idiopathic short stature (familial, constitutional delayed puberty) refers to those who exclude growth hormone deficiency, small for gestational age, systemic diseases, etc., but the height of the child is lower than […]
07/04/2021

The application and principle of Triptorelin(cas 57773-63-4)

Triptorelin is often used clinically to treat patients who need to reduce steroid hormones such as male hormones and estrogen to low levels. It can also be used as a treatment for male prostate cancer. It is also common in the treatment of female infertility diseases. , Also has a certain reputation in the field of assisted reproduction.
This product is an analog of synthetic gonadotropin releasing hormone. The clinical effect is definite. It is the world's first sustained-release gonadotropin releasing hormone analogue put on the market, and its activity is 100 times that of natural hormones. The preparation has been on the market in more than 80 countries around the world, which fully proves that this product is safe and effective.
07/04/2021

What is Phenibut?

Phenytoin is a "nootropic drug" that has multiple effects on the body and nervous system. Nootropics are drugs that enhance memory or stimulate specific areas of the brain. It is also used to treat conditions such as anxiety and insomnia. People with generalized anxiety disorder (GAD) may benefit from taking phenibbuter. The technical name of the drug is β-phenyl-γ-aminobutyric acid, which is a derivative of γ-aminobutyric acid, a neuromodulator, and GABA (and its derivatives, such as phenytoin sodium) has been proven to have some Predictive effects make these chemicals useful for certain treatments. Phenibut is a nootropic, sometimes used to treat anxiety. This drug was originally a "astronaut's medicine."
06/04/2021
CD19/CD22 dual target car-t therapy

Clinical efficacy report of Linaclotide

Background and overview Linaclotide (trade name LINZESS) is a new type of GC-C (intestinal epithelial cell uridine cyclase C) receptor agonist developed by Ironwood. It activates the GC-C receptor on the top of intestinal epithelial cells, leading to an increase in intracellular and extracellular cyclic guanosine phosphate. Its effect is to increase the secretion of chlorine and bicarbonate into the intestinal cavity, which leads to increased fluid secretion and accelerated stool. It is used to treat adult patients with slow transit constipation and constipation-type irritable bowel syndrome (IBS-C).
BUY NOW